Drugs / Zirconium-89 crefmirlimab berdoxam
Zirconium-89 crefmirlimab berdoxam
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05397171 | Jun 2022 → Jun 2023 | colorectal cancer, non-small cell lung carcinoma, urinary bladder cancer | AstraZeneca | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zirconium-89 crefmirlimab berdoxam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05397171 ↗ |
| Modality | Diagnostic / imaging agent | “CD8+ T cell tracer for positron emission tomography (PET) at two time points in addition to monotherapy AZD8853” NCT05397171 ↗ |